Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting
Vertigo
About this trial
This is an interventional treatment trial for Vertigo focused on measuring BPPV, Meniere's disease, Migraine associated vertigo, Labyrinthitis, Vestibular neuritis
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects age 18 to 70 years old
- Vertigo that has been present for at least 90 days
- Vertigo that is constant or predictable
- Consulted a medical doctor in the past 24 months regarding their vertigo
- Identify as having vertigo from one of the following causes:
- Benign Paroxysmal Positional Vertigo (BPPV)
- Meniere's Disease
- Vestibular Migraines
- Migraine Associated Vertigo
- Vestibular Neuritis
- Labyrinthitis
- Vertigo caused by COVID-19
- Score within appropriate range on the Dizziness Handicap Inventory
- Have a computer and access to internet for online video conferences
- PayPal, Venmo or Zelle account to receive compensation
Exclusion Criteria:
- Vertigo that first presented within the last 90 days
- Skull base surgery within the last 90 days
- Any skull implant (cochlear implant, bone conduction implant, DBS)
- Taking benzodiazepines (e.g., clonazepam, lorazepam, diazepam) for dizziness
- Vitreous detachment of the retina (floaters in the eye) in the previous 90 days
Sites / Locations
- Otolith Labs
Arms of the Study
Arm 1
Arm 2
Other
Other
Otoband efficacy versus Sham A
Otoband efficacy versus Sham B
Participants in Arm 1 will receive, in random order, an OtoBand or Sham Device A to use for two weeks each. Sham Device A is an OtoBand in which the transducer is modified so that the vibrations do not target the vestibular system. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham or effective).
Participants in Arm 2 will receive, in random order, a OtoBand or Sham Device B. Sham Device B is an OtoBand that operates at settings found to be non-therapeutic in motion sickness studies. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham, or effective).